Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026

Rhea-AI Summary

Revelation Biosciences (NASDAQ:REVB) will implement a 1-for-4 reverse stock split effective the morning of January 28, 2026. Post-split shares will begin trading that day under the existing symbol REVB and a new CUSIP 76135L804 will apply. The reverse split is intended to increase the share price to regain compliance with The Nasdaq Capital Market's minimum bid continued listing requirement. Proportionate adjustments will be made to warrants, restricted stock units and stock options. Fractional shares resulting from the split will be rounded up to the nearest whole share.

Positive

• 1-for-4 reverse split effective January 28, 2026
• Action intended to regain Nasdaq minimum bid compliance
• Proportionate adjustments to warrants, RSUs, and options

Negative

• Fractional shares will be rounded up, modestly increasing shares outstanding
• Position adjustments for holders via brokers may vary by broker process

Market Reaction

-4.04% $0.53 1.7x vol

15m delay 41 alerts

-4.04% Since News

$0.53 Last Price

$0.52 $0.61 Day Range

-$137K Valuation Impact

$3M Market Cap

1.7x Rel. Volume

Following this news, REVB has declined 4.04%, reflecting a moderate negative market reaction. Our momentum scanner has triggered 41 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $0.53. This price movement has removed approximately $137K from the company's valuation. Trading volume is above average at 1.7x the average, suggesting increased trading activity.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.

Key Figures

Reverse split ratio: 1-for-4 Effective date: January 28, 2026 New CUSIP: 76135L804 +3 more

6 metrics

Reverse split ratio 1-for-4 Common stock reverse split effective January 28, 2026

Effective date January 28, 2026 Reverse stock split effectiveness and start of post-split trading

New CUSIP 76135L804 CUSIP for common stock following reverse split

Pre-split shares per post-split share 4 shares into 1 Each four issued and outstanding shares combined into one

Transfer agent phone (212) 509-4000 Continental Stock Transfer & Trust Co. contact number

Toll-free phone (800) 509-5586 Continental Stock Transfer & Trust Co. toll-free line

Market Reality Check

Price: $0.5501 Vol: Volume 91,559,768 is 16.2...

high vol

$0.5501 Last Close

Volume Volume 91,559,768 is 16.29x the 20-day average of 5,620,546, highlighting elevated trading around the reverse split news. high

Technical Shares at $0.6459 are trading below the 200-day moving average of $3.02, keeping the stock in a weak technical posture ahead of the 1-for-4 reverse split.

Peers on Argus

REVB is down 24.4% with very high volume, while momentum peers XRTX and SPRC sho...

1 Up 2 Down

REVB is down 24.4% with very high volume, while momentum peers XRTX and SPRC show declines of -7.509999722242355% and -7.609999924898148%. One peer, DRMA, is up 13.459999859333038%. Overall, sector pressure is present but REVB’s move is markedly larger, pointing to company-specific impact from the reverse split and recent financing.

Common Catalyst No same-day peer news headlines; moves appear driven by broader biotech momentum with REVB additionally reacting to its reverse split and recent capital actions.

Previous Stock split Reports

2 past events · Latest: Jul 01 (Neutral)

Same Type Pattern 2 events

Date	Event	Sentiment	Move	Catalyst
Jul 01	Reverse stock split	Neutral	-6.1%	Announced 1-for-3 reverse split to regain Nasdaq minimum bid compliance.
Jan 24	Reverse stock split	Neutral	-23.8%	Announced 1-for-16 reverse split aimed at restoring Nasdaq bid compliance.

Pattern Detected

Past reverse stock split announcements for REVB have been followed by notable negative price reactions, suggesting this type of corporate action has historically weighed on the shares.

Recent Company History

Over the past year, REVB has repeatedly used reverse stock splits to address Nasdaq minimum bid requirements. A 1-for-16 split on Jan 24, 2025 saw a -23.84% move, and a 1-for-3 split on Jul 01, 2025 saw a -6.09% move. Today’s 1-for-4 reverse split continues this pattern of structural actions to sustain listing compliance, against a backdrop of ongoing clinical and financing activity noted in other filings.

Historical Comparison

stock split

+15.0 %

Average Historical Move

Historical Analysis

In the past year, REVB announced 2 reverse stock splits tagged as ‘stock split,’ with an average absolute move of 14.96%. Today’s action fits a recurring pattern of structural listing-compliance measures.

Typical Pattern

REVB has implemented multiple reverse stock splits (1-for-16, 1-for-3, now 1-for-4) from 2025 through 2026, consistently framing them as tools to maintain Nasdaq minimum bid compliance.

Regulatory & Risk Context

Active S-3 Shelf · $28,743,000

Shelf Active

Active S-3 Shelf Registration 2025-09-29

$28,743,000 registered capacity

An active Form S-3/A dated 2025-09-29 registers common shares underlying Class I warrants at $2.20 per share. The company may receive up to $28,743,000 in proceeds if all registered warrants are exercised for cash. The shelf is effective through 2028-09-29 with no recorded usage to date.

Market Pulse Summary

This announcement details a 1-for-4 reverse stock split effective January 28, 2026, aimed at regaini...

Analysis

This announcement details a 1-for-4 reverse stock split effective January 28, 2026, aimed at regaining Nasdaq’s minimum bid compliance while leaving ownership percentages largely unchanged. It follows earlier reverse splits in 2025 and comes on top of warrant-driven financings and an effective shelf that may generate up to $28,743,000 from Class I warrant exercises. Investors typically track how these structural steps interact with clinical progress and future capital needs.

Key Terms

reverse stock split, cusip number, warrants, restricted stock unit awards, +4 more

8 terms

reverse stock split financial

"the Company will implement a 1-for-4 reverse split of its common stock."

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

cusip number financial

"The CUSIP number for the common stock following the reverse stock split will be 76135L804."

A CUSIP number is a nine-character code that uniquely identifies a specific U.S. or Canadian stock, bond, or other security, similar to a barcode or a social-security number for a financial instrument. It matters to investors because it removes confusion between similar securities, ensures trades and settlements are applied to the correct issue, and helps locate official documents and transaction records quickly.

warrants financial

"adjustments will be made to the conversion and exercise prices of the company's warrants, restricted stock unit awards, stock options"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

restricted stock unit awards financial

"conversion and exercise prices of the company's warrants, restricted stock unit awards, stock options"

Restricted stock unit awards are company promises to deliver a specific number of shares to employees or service providers in the future once conditions—such as staying with the company for a set time or meeting performance targets—are met. They matter to investors because when the promises convert into actual shares they increase the total share count and can reduce earnings per share, while also aligning recipients’ interests with stock performance much like deferred pay that turns into ownership if goals are met.

stock options financial

"conversion and exercise prices of the company's warrants, restricted stock unit awards, stock options"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

equity incentive plans financial

"and to the number of shares issued and issuable under the Company's equity incentive plans."

Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.

transfer agent financial

"The Company's transfer agent, Continental Stock Transfer & Trust Co., will maintain the book-entry records"

A transfer agent is a financial service that keeps the official record of who owns a company's shares, handles the buying and selling of those shares on paper or electronically, and issues or cancels stock certificates. Think of it as the company’s records keeper and mailroom combined—investors rely on it to make sure dividends, shareholder mailings, ownership changes, and proxy voting are processed accurately and securely, which protects ownership rights and helps prevent errors or fraud.

book-entry financial

"Registered stockholders holding pre-split shares of the Company's common stock electronically in book-entry form"

A book-entry is an electronic record that shows who legally owns a share, bond or other security instead of a paper certificate. Think of it like a bank ledger entry that tracks ownership and transfers; it makes buying, selling, dividend payments and ownership checks faster, cheaper and less risky for investors because nothing physical needs to be moved or stored.

AI-generated analysis. Not financial advice.

SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), announced today that, on January 28, 2026, the Company will implement a 1-for-4 reverse split of its common stock. The reverse stock split will be effective as of the morning of January 28, 2026, and the Company's common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol "REVB." The CUSIP number for the common stock following the reverse stock split will be 76135L804.

The reverse stock split is intended to increase the market price per share of the Company's common stock to regain compliance with the minimum bid continued listing requirement of The Nasdaq Capital Market. Proportionate adjustments will be made to the conversion and exercise prices of the company's warrants, restricted stock unit awards, stock options and to the number of shares issued and issuable under the Company's equity incentive plans.

Information for Stockholders

Upon the effectiveness of the reverse stock split, each four shares of the Company's issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder's relative interest in the Company's equity, except to the extent that the reverse stock split would have resulted in a stockholder owning a fractional share. Holders of common stock otherwise entitled to a fractional share as a result of the Reverse Stock Split because they hold a number of shares not evenly divisible by the Reverse Stock Split ratio will be rounded up to the nearest whole share. The reverse stock split will not change the par value of the common stock or modify the rights or preferences of the common stock. The Company's transfer agent, Continental Stock Transfer & Trust Co., will maintain the book-entry records for the Company's common stock. Registered stockholders holding pre-split shares of the Company's common stock electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning shares via a broker, bank, trust or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to such broker's particular processes, and will not be required to take any action in connection with the reverse stock split. Continental Stock Transfer & Trust Co. can be reached at (212) 509-4000 or (800)-509-5586.

About Revelation Biosciences, Inc.

Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation, Gemini. Revelation has multiple ongoing programs to evaluate Gemini as a treatment for acute kidney injury, a treatment of chronic kidney disease, prevention of post-surgical infection, and a treatment to reduce hyperinflammation and infection associated with severe burn.

For more information, please visit www.RevBiosciences.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management's expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation's product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation's balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.

Company Contacts

Mike Porter
Investor Relations
Porter LaVay & Rose Inc.
Email: mike@plrinvest.com

Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com

SOURCE: Revelation Biosciences, Inc.

View the original press release on ACCESS Newswire

FAQ

What is the reverse stock split ratio for Revelation Biosciences (REVB)?

Revelation announced a 1-for-4 reverse stock split effective January 28, 2026.

When will REVB trade on a post-split basis and under what symbol?

Shares will trade on a post-split basis at the start of trading on January 28, 2026 under the existing symbol REVB.

Will my warrants, stock options, or RSUs be affected by the REVB reverse split?

Yes; the company will make proportionate adjustments to conversion and exercise prices and to the number of shares issuable.

What happens if I would receive a fractional share after the REVB reverse split?

Holders entitled to fractional shares will be rounded up to the nearest whole share.

Will the REVB CUSIP or transfer agent change after the reverse split?

Yes; the post-split CUSIP will be 76135L804 and Continental Stock Transfer & Trust Co. will maintain book-entry records.

Do shareholders need to take any action to receive post-split REVB shares?

Registered stockholders in book-entry form need not act; brokered accounts will be adjusted automatically subject to each broker's processes.